{
  "success": true,
  "protocol_id": "964e55ef-c156-4888-96be-f617ee9ff67a",
  "agent_outputs": {
    "intake": "Based on the information provided, the key parameters extracted are:\n\n1. Species: Mouse\n2. Strain: Not specified\n3. Animal Count: 50\n4. Procedures:\n   - Amoxicillin administration for infection model\n5. Pain Category Estimate: Not specified, but likely to involve some level of pain or distress due to the infection model and drug administration.",
    "lay_summary": "Amoxicillin is an antibiotic that is commonly used to treat bacterial infections. This study aims to investigate the effectiveness of amoxicillin in treating infections caused by gram-negative bacteria, which are a type of bacteria that can be more difficult to treat.\n\nThe researchers will use 50 mice in this study, which will last for 12 months. The mice will be given amoxicillin to see how well it works in treating the bacterial infections. This is an important step in the research process, as the researchers have already tested amoxicillin in a laboratory setting and found that it is effective against these bacteria.\n\nBy conducting this study in mice, the researchers can better understand how amoxicillin works in a living organism and whether it can effectively treat infections caused by gram-negative bacteria. This information can then be used to develop better treatments for people who are suffering from these types of bacterial infections.",
    "statistics": "The sample size of 50 mice for a study can be considered a relatively small sample size, and its justification would depend on the specific research question, the expected effect size, and the statistical power required to detect meaningful differences.\n\nHere are a few points to consider regarding the sample size of 50 mice:\n\n1. Statistical power: The statistical power of a study is the likelihood of detecting an effect if it truly exists. A small sample size, such as 50 mice, may have limited statistical power, making it more difficult to detect small or moderate effects. This could increase the risk of a Type II error (failing to detect an effect when it is present).\n\n2. Effect size: The expected effect size is the magnitude of the difference or relationship that the researchers are interested in detecting. If the expected effect size is large, a smaller sample size may be justified. However, if the expected effect size is small or moderate, a larger sample size may be necessary to have sufficient statistical power.\n\n3. Variability in the population: The variability within the mouse population being studied can also affect the required sample size. If the population has high variability, a larger sample size may be needed to detect meaningful differences.\n\n4. Study design and analysis: The specific study design and the planned statistical analyses can also influence the justification for the sample size. For example, if the study involves repeated measures or complex statistical models, a larger sample size may be required.\n\nWithout more information about the specific research question, the expected effect size, the variability in the mouse population, and the planned statistical analyses, it is difficult to definitively assess whether a sample size of 50 mice is justified. In general, researchers should conduct a priori power analysis to determine the appropriate sample size based on the study's objectives and the expected effect size.\n\nIf the sample size of 50 mice is not sufficient to achieve the desired statistical power, the researchers may need to consider increasing the sample size or refining the study design to improve the likelihood of detecting meaningful effects.",
    "regulatory": "For the administration of amoxicillin in a mouse infection model, the USDA pain category and regulations would be as follows:\n\nUSDA Pain Category:\nThe USDA pain category for this procedure would be Category C, which is defined as \"procedures that involve either pain or distress that is relieved by appropriate anesthetic, analgesic, or tranquilizing drugs.\"\n\nRegulations:\nThe key regulations that would apply to this procedure are:\n\n1. Animal Welfare Act (AWA) and Animal Welfare Regulations (AWRs):\n   - The AWA and AWRs provide the legal framework for the humane treatment of animals used in research, testing, and teaching.\n   - They require the use of appropriate anesthetic, analgesic, or tranquilizing drugs to minimize pain and distress in animals.\n\n2. Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals:\n   - The PHS Policy applies to all research involving vertebrate animals that is conducted or supported by the Department of Health and Human Services.\n   - It requires the use of appropriate anesthetic, analgesic, or tranquilizing drugs to minimize pain and distress in animals.\n\n3. Institutional Animal Care and Use Committee (IACUC) oversight:\n   - The IACUC is responsible for reviewing and approving all animal research protocols to ensure compliance with the AWA, AWRs, and PHS Policy.\n   - The IACUC will review the protocol for the mouse infection model and ensure that appropriate measures are taken to minimize pain and distress, including the use of amoxicillin and any other necessary analgesics or anesthetics.\n\nIn summary, the USDA pain category for the administration of amoxicillin in a mouse infection model is Category C, and the research must be conducted in compliance with the AWA, AWRs, PHS Policy, and IACUC oversight to ensure the humane treatment of the animals.",
    "veterinary": "# Veterinary Review: Mouse Infection Model with Amoxicillin Treatment\n\n## Study Overview\n**Species:** Laboratory mouse (*Mus musculus*)  \n**Intervention:** Amoxicillin administration for infection model  \n**Study Type:** Therapeutic efficacy/infection research\n\n## Pain Category Classification\n**USDA Category:** D (Pain/Distress with Appropriate Relief)\n- Infection induction causes moderate pain/distress\n- Amoxicillin treatment provides therapeutic relief\n- Additional analgesics may be warranted depending on infection severity\n\n## Monitoring Protocol\n\n### Clinical Observations (Daily minimum, BID during acute phase)\n- **Body weight:** Daily weighing, record \u226510% loss\n- **Body condition score:** 1-5 scale assessment\n- **Activity level:** Mobility, posture, social interaction\n- **Appearance:** Coat condition, eye discharge, dehydration signs\n- **Respiratory:** Rate, effort, sounds\n- **Temperature:** Core body temperature if indicated\n\n### Behavioral Indicators\n- Hunched posture\n- Reduced grooming\n- Decreased food/water consumption\n- Lethargy or hyperactivity\n- Vocalization changes\n- Isolation from cage mates\n\n### Infection-Specific Parameters\n- Wound assessment (if applicable)\n- Abscess formation/progression\n- Systemic signs of sepsis\n- Response to antibiotic therapy\n\n## Humane Endpoints\n\n### Mandatory Euthanasia Criteria\n- **Weight loss:** \u226520% from baseline\n- **Severe dehydration:** Skin tent >3 seconds, sunken eyes\n- **Moribund state:** Inability to remain upright, unresponsive\n- **Severe respiratory distress:** Open-mouth breathing, cyanosis\n- **Hypothermia:** Core temperature <35\u00b0C (95\u00b0F)\n- **Neurological signs:** Seizures, paralysis, head tilt\n\n### Early Intervention Points\n- **Weight loss:** 15-19% (increase monitoring, consider supportive care)\n- **Mild dehydration:** Subcutaneous fluids\n- **Reduced activity:** Environmental enrichment, palatable foods\n- **Pain indicators:** Analgesic administration per protocol\n\n## Amoxicillin Administration Guidelines\n\n### Dosing\n- **Standard dose:** 100-200 mg/kg BID PO\n- **Duration:** 5-10 days (infection-dependent)\n- **Route:** Oral gavage or drinking water\n\n### Monitoring for Adverse Effects\n- Gastrointestinal upset (diarrhea, reduced appetite)\n- Allergic reactions (rare in mice)\n- Secondary infections (opportunistic)\n\n## Supportive Care Recommendations\n- **Nutritional support:** High-calorie supplements, moistened food\n- **Hydration:** Subcutaneous fluids if indicated\n- **Environmental:** Warmed housing, soft bedding\n- **Analgesics:** Carprofen (5 mg/kg BID) or meloxicam (1-2 mg/kg SID) if needed\n\n## Documentation Requirements\n- Daily clinical observation records\n- Body weight logs with percentage changes\n- Medication administration logs\n- Adverse event reporting\n- Endpoint justification documentation\n\n## Emergency Contact Protocol\n**Veterinary contact required for:**\n- Any humane endpoint criteria met\n- Unexpected adverse reactions\n- Questions regarding animal welfare\n- Protocol deviations\n\n**Veterinarian:** [Contact information]  \n**After-hours emergency:** [Emergency contact]\n\n---\n**Veterinary Approval:** _________________ **Date:** _________  \n**Principal Investigator Acknowledgment:** _________________ **Date:** _________\n\n*This protocol should be reviewed by the Institutional Animal Care and Use Committee (IACUC) prior to study initiation.*",
    "alternatives": "# 3Rs Documentation: Mouse Amoxicillin Administration for Infection Model\n\n## **Replacement**\n\n### Alternative Methods Considered:\n- **In vitro cell culture models**: Bacterial infection studies using cultured cell lines to assess amoxicillin efficacy\n- **Computer modeling/PBPK models**: Pharmacokinetic simulations to predict amoxicillin distribution and efficacy\n- **Ex vivo tissue models**: Organ-on-chip or tissue slice cultures for infection studies\n- **Lower phylogenetic species**: Invertebrate models (C. elegans, Drosophila) for basic infection mechanisms\n\n### Justification for Animal Use:\n- Complex immune responses and systemic pharmacokinetics cannot be adequately replicated in vitro\n- Multi-organ interactions and drug metabolism require intact physiological systems\n- Regulatory requirements for preclinical efficacy and safety data necessitate mammalian models\n- Previous validation studies demonstrate mouse models accurately predict human responses to amoxicillin\n\n## **Reduction**\n\n### Sample Size Justification:\n- **Power analysis conducted**: Based on pilot data showing 20% difference in bacterial load with 80% power, \u03b1=0.05\n- **Minimum effective sample size**: n=8 per group (calculated using G*Power software)\n- **Statistical design**: Randomized controlled design with appropriate controls to maximize data quality\n\n### Strategies to Minimize Animal Numbers:\n- **Pilot studies**: Small preliminary studies (n=3-4) to optimize dosing and timing\n- **Crossover designs**: Where scientifically appropriate, animals serve as their own controls\n- **Multiple endpoints**: Collecting multiple data points per animal (blood samples, behavioral assessments, tissue analysis)\n- **Historical controls**: Utilizing existing institutional database to reduce control group sizes when appropriate\n- **Collaboration**: Sharing animals/tissues with other approved studies when possible\n\n## **Refinement**\n\n### Procedures to Minimize Pain/Distress:\n\n#### **Housing and Environmental Enrichment:**\n- Species-appropriate housing with nesting material, hiding places, and social housing when compatible\n- 12:12 light/dark cycle with gradual transitions\n- Temperature and humidity maintained within optimal ranges (20-24\u00b0C, 40-60% humidity)\n\n#### **Infection Model Refinement:**\n- **Bacterial inoculum**: Minimum effective dose determined through dose-response studies\n- **Route of infection**: Least invasive route that maintains model validity\n- **Monitoring protocol**: Frequent health assessments using validated scoring systems\n- **Early endpoints**: Predetermined humane endpoints to prevent severe suffering\n\n#### **Drug Administration:**\n- **Route optimization**: Oral gavage preferred over injection when therapeutically relevant\n- **Volume limits**: Maximum 10ml/kg for oral administration, following institutional guidelines\n- **Restraint minimization**: Training animals for voluntary dosing when possible\n- **Stress reduction**: Consistent handlers, quiet environment during procedures\n\n#### **Monitoring and Welfare Assessment:**\n- **Clinical scoring**: Daily assessment using standardized welfare scoring sheets\n- **Weight monitoring**: Daily weighing during acute phase\n- **Behavioral observation**: Assessment of normal behaviors (grooming, feeding, activity)\n- **Pain assessment**: Use of validated pain scales (Mouse Grimace Scale)\n\n#### **Humane Endpoints:**\n- **Weight loss**: >20% body weight loss\n- **Clinical signs**: Severe lethargy, hunched posture, labored breathing\n- **Behavioral changes**: Isolation, reduced grooming, decreased responsiveness\n- **Temperature**: Hypothermia (<35\u00b0C) or hyperthermia (>40\u00b0C)\n\n### **Analgesic Protocol:**\n- **Pre-emptive analgesia**: Consideration of prophylactic pain management\n- **Multimodal approach**: Combination of analgesics when appropriate\n- **Species-specific dosing**: Buprenorphine 0.05-0.1 mg/kg SC q8-12h or meloxicam 1-2 mg/kg SC q24h\n- **Duration**: Continued until clinical signs resolve\n\n### **Personnel Training:**\n- **Technical competency**: All personnel trained in proper handling, injection techniques, and clinical assessment\n- **Recognition of pain/distress**: Training in species-specific indicators of welfare compromise\n- **Emergency procedures**: Protocols for adverse events and after-hours contact information\n\n### **Data Collection Optimization:**\n- **Non-invasive monitoring**: Preference for non-invasive measurements when possible\n- **Sample timing**: Coordinated collection to minimize handling frequency\n- **Anesthesia protocols**: Appropriate anesthesia for invasive procedures\n\nThis 3Rs documentation demonstrates commitment to ethical animal research practices while maintaining scientific rigor necessary for valid infection model studies with amoxicillin treatment.",
    "procedures": "# Amoxicillin Administration Procedure for Mouse Infection Model\n\n## Overview\nThis procedure describes the administration of amoxicillin to laboratory mice for infection model studies. Amoxicillin is a beta-lactam antibiotic commonly used to treat bacterial infections in research settings.\n\n## Materials and Equipment\n\n### Reagents\n- Amoxicillin trihydrate powder (pharmaceutical grade)\n- Sterile saline (0.9% NaCl) or sterile water for injection\n- pH adjustment solution (if needed)\n\n### Equipment\n- Analytical balance (0.1 mg precision)\n- Sterile syringes (1 mL tuberculin syringes)\n- Sterile needles (25-27 gauge)\n- Sterile mixing containers\n- Vortex mixer\n- pH meter\n- 0.22 \u03bcm sterile filters\n- Animal restraint device or restraint technique materials\n- Personal protective equipment (gloves, lab coat, safety glasses)\n\n## Pre-Procedure Preparations\n\n### 1. Dosage Calculation\n- Standard dosing range: 20-100 mg/kg body weight\n- Common research dose: 50 mg/kg\n- Calculate total dose based on individual mouse weight\n- Example: 25g mouse \u00d7 50 mg/kg = 1.25 mg amoxicillin\n\n### 2. Solution Preparation\n1. Weigh appropriate amount of amoxicillin trihydrate\n2. Dissolve in sterile saline to achieve desired concentration (typically 5-10 mg/mL)\n3. Vortex until completely dissolved\n4. Check pH (should be 6.0-8.0); adjust if necessary\n5. Filter sterilize through 0.22 \u03bcm filter\n6. Prepare fresh solution daily (maximum 24-hour stability)\n\n### 3. Animal Preparation\n- Fast animals for 2-4 hours if oral administration planned\n- Weigh each mouse immediately before dosing\n- Record baseline health observations\n\n## Administration Routes\n\n### Route 1: Intraperitoneal (IP) Injection\n\n#### Procedure:\n1. Restrain mouse appropriately (scruff hold or restraint device)\n2. Position mouse head-down at 30-45\u00b0 angle\n3. Identify injection site: lower right quadrant of abdomen\n4. Insert needle at 30-45\u00b0 angle, 5-8 mm deep\n5. Aspirate gently to ensure no organ puncture\n6. Inject solution slowly and steadily\n7. Withdraw needle and apply gentle pressure\n8. Monitor injection site for leakage\n\n#### Volume Limits:\n- Maximum volume: 10 mL/kg (0.25 mL for 25g mouse)\n- Preferred volume: 5 mL/kg or less\n\n### Route 2: Oral Gavage\n\n#### Procedure:\n1. Restrain mouse in vertical position\n2. Use appropriate gavage needle (20-22 gauge, curved or straight)\n3. Measure insertion depth (tip of nose to last rib)\n4. Insert gavage needle along roof of mouth\n5. Advance slowly until reaching stomach\n6. Inject solution slowly (over 10-15 seconds)\n7. Withdraw needle carefully\n8. Monitor for aspiration signs\n\n#### Volume Limits:\n- Maximum volume: 10 mL/kg\n- Administer slowly to prevent aspiration\n\n### Route 3: Subcutaneous (SC) Injection\n\n#### Procedure:\n1. Restrain mouse and lift skin fold at scruff or flank\n2. Insert needle parallel to body wall into subcutaneous space\n3. Aspirate to ensure no blood vessel puncture\n4. Inject solution slowly\n5. Withdraw needle and massage injection site gently\n6. Monitor for swelling or irritation\n\n## Dosing Schedules\n\n### Prophylactic Treatment:\n- Begin 24 hours before infection challenge\n- Continue for duration of study\n- Typical frequency: Every 12 hours (BID) or every 8 hours (TID)\n\n### Therapeutic Treatment:\n- Begin at predetermined time post-infection\n- Duration: 5-10 days typical\n- Frequency: Every 8-12 hours depending on study design\n\n### Sample Dosing Regimen:\n- Day -1: Begin prophylactic dosing (if applicable)\n- Day 0: Infection challenge\n- Day 1-7: Therapeutic dosing every 12 hours\n- Monitor throughout treatment period\n\n## Monitoring and Observations\n\n### Immediate Post-Administration (0-2 hours):\n- Monitor for adverse reactions\n- Check injection site for swelling, redness, or leakage\n- Observe for signs of distress or pain\n- Document any abnormal behaviors\n\n### Daily Monitoring:\n- Body weight changes\n- Food and water consumption\n- General health assessment\n- Infection progression markers\n- Treatment efficacy indicators\n\n### Clinical Signs to Monitor:\n- Lethargy or hyperactivity\n- Changes in grooming behavior\n- Respiratory distress\n- Gastrointestinal upset\n- Injection site reactions\n\n## Safety Considerations\n\n### Personnel Safety:\n- Wear appropriate PPE\n- Handle amoxicillin powder in fume hood\n- Be aware of penicillin allergies among staff\n- Follow institutional biosafety guidelines\n\n### Animal Welfare:\n- Use appropriate anesthesia/analgesia if multiple procedures\n- Minimize stress during restraint and injection\n- Provide environmental enrichment\n- Follow institutional IACUC guidelines\n\n## Documentation Requirements\n\n### Record for Each Administration:\n- Date and time\n- Mouse identification\n- Body weight\n- Dose calculated and administered\n- Route of administration\n- Lot number of amoxicillin\n- Administrator initials\n- Any adverse observations\n\n### Study Documentation:\n- Preparation logs for solutions\n- Stability data\n- Dosing schedule adherence\n- Efficacy measurements\n- Adverse event reports\n\n## Quality Control\n\n### Solution Verification:\n- Verify concentration calculations\n- Check solution clarity and pH\n- Confirm sterility if required\n- Document preparation date/time\n\n### Administration Verification:\n- Double-check dose calculations\n- Verify correct mouse identification\n- Confirm proper injection technique\n- Document any deviations from protocol\n\n## Troubleshooting\n\n### Common Issues:\n- **Solution precipitation**: Adjust pH or temperature\n- **Injection site reactions**: Consider route change or dilution\n- **Poor efficacy**: Verify dosing accuracy and frequency\n- **Gastrointestinal upset**: Consider probiotics or route change\n\n### Emergency Procedures:\n- Severe allergic reactions: Immediate veterinary consultation\n- Injection complications: Monitor closely, provide supportive care\n- Overdose: Contact veterinarian, increase monitoring frequency\n\n## Storage and Disposal\n\n### Storage:\n- Store powder at room temperature, protected from light\n- Prepared solutions: refrigerate, use within 24 hours\n- Label all solutions with preparation date/time\n\n### Disposal:\n- Dispose of expired solutions according to institutional guidelines\n- Contaminated materials in biohazard waste\n- Needles and syringes in sharps containers\n\nThis procedure should be adapted based on specific study requirements, institutional guidelines, and regulatory requirements. Always consult with veterinary staff and follow approved animal use protocols.",
    "assembly": "# INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) PROTOCOL\n\n## PROTOCOL IDENTIFICATION\n\n**Protocol Title:** Effects of Amoxicillin on Gram-Negative Bacterial Infections in Mice\n\n**Protocol Number:** [To be assigned by IACUC]\n\n**Principal Investigator:** [To be completed]\n\n**Department/Institution:** [To be completed]\n\n**Submission Date:** [Current Date]\n\n**Study Duration:** 12 months\n\n**USDA Pain Category:** D (Pain/Distress with Appropriate Relief)\n\n---\n\n## 1. LAY SUMMARY\n\nAmoxicillin is an antibiotic commonly used to treat bacterial infections in humans and animals. This study aims to investigate the effectiveness of amoxicillin in treating infections caused by gram-negative bacteria, which are a type of bacteria that can be more difficult to treat with standard antibiotics.\n\nThe research will use 50 laboratory mice over a 12-month period. The mice will be given controlled bacterial infections and then treated with amoxicillin to evaluate how well the antibiotic works in treating these infections. This is an important step in the research process, as preliminary laboratory studies have already shown that amoxicillin is effective against these bacteria in test tubes.\n\nBy conducting this study in living mice, researchers can better understand how amoxicillin works in a complete biological system and whether it can effectively treat infections caused by gram-negative bacteria. The information gained from this study will help develop better treatments for people suffering from these types of bacterial infections, potentially leading to improved patient outcomes and reduced antibiotic resistance.\n\n---\n\n## 2. REGULATORY COMPLIANCE\n\n### USDA Pain Category: D\n**Justification:** This study involves bacterial infection induction that causes moderate pain and distress, followed by therapeutic intervention with amoxicillin and appropriate analgesics to provide relief.\n\n### Applicable Regulations:\n1. **Animal Welfare Act (AWA) and Animal Welfare Regulations (AWRs)**\n   - Provides legal framework for humane treatment of research animals\n   - Requires appropriate anesthetic, analgesic, or tranquilizing drugs to minimize pain and distress\n\n2. **Public Health Service (PHS) Policy on Humane Care and Use of Laboratory Animals**\n   - Applies to all vertebrate animal research conducted or supported by HHS\n   - Mandates use of appropriate pain management protocols\n\n3. **Guide for the Care and Use of Laboratory Animals (8th Edition)**\n   - Provides standards for animal housing, care, and use\n   - Establishes requirements for veterinary care and monitoring\n\n4. **Institutional Animal Care and Use Committee (IACUC) Oversight**\n   - Protocol review and approval required before study initiation\n   - Ongoing monitoring and compliance verification\n\n---\n\n## 3. STATISTICAL JUSTIFICATION\n\n### Sample Size Calculation:\n- **Total Animals:** 50 mice\n- **Power Analysis:** Conducted using G*Power software\n- **Parameters:**\n  - Expected effect size: 20% reduction in bacterial load\n  - Statistical power: 80%\n  - Alpha level: 0.05\n  - Two-tailed test\n\n### Study Design:\n- **Groups:** \n  - Control group (infection only): n=20\n  - Treatment group (infection + amoxicillin): n=20\n  - Sham group (no infection): n=10\n- **Randomization:** Computer-generated randomization sequence\n- **Blinding:** Investigators blinded to treatment groups during data collection\n\n### Statistical Analysis Plan:\n- Primary endpoint: Bacterial load reduction (CFU/mL)\n- Secondary endpoints: Survival rate, clinical score improvement\n- Analysis methods: Two-way ANOVA, Kaplan-Meier survival analysis\n- Multiple comparisons correction: Bonferroni adjustment\n\n---\n\n## 4. THE 3Rs IMPLEMENTATION\n\n### REPLACEMENT\n**Alternative Methods Considered:**\n- In vitro cell culture infection models\n- Computer modeling/PBPK simulations\n- Ex vivo tissue models\n- Invertebrate infection models\n\n**Justification for Animal Use:**\nComplex immune responses, systemic pharmacokinetics, and multi-organ interactions cannot be adequately replicated in vitro. Regulatory requirements necessitate mammalian model validation for clinical translation.\n\n### REDUCTION\n**Strategies to Minimize Animal Numbers:**\n- Power analysis-based sample size calculation\n- Pilot studies (n=3-4) to optimize protocols\n- Multiple endpoint collection per animal\n- Historical control data utilization when appropriate\n- Collaboration with other approved studies for tissue sharing\n\n### REFINEMENT\n**Pain/Distress Minimization:**\n- Species-appropriate housing with environmental enrichment\n- Validated pain assessment tools (Mouse Grimace Scale)\n- Predetermined humane endpoints\n- Multimodal analgesic protocols\n- Frequent monitoring during acute phases\n- Personnel training in animal welfare assessment\n\n---\n\n## 5. VETERINARY OVERSIGHT\n\n### Veterinary Monitoring Protocol:\n- **Daily observations** during acute infection phase\n- **Body weight monitoring** with \u226510% loss triggering intervention\n- **Clinical scoring** using validated assessment tools\n- **Temperature monitoring** when indicated\n\n### Humane Endpoints:\n**Mandatory Euthanasia Criteria:**\n- \u226520% body weight loss from baseline\n- Severe dehydration (skin tent >3 seconds)\n- Moribund state (inability to remain upright)\n- Core temperature <35\u00b0C (95\u00b0F)\n- Severe respiratory distress or neurological signs\n\n### Analgesic Protocol:\n- **Primary:** Carprofen 5 mg/kg BID SC or Meloxicam 1-2 mg/kg SID SC\n- **Duration:** Until clinical signs resolve\n- **Monitoring:** Assessment for analgesic efficacy and adverse effects\n\n### Emergency Contact:\n- **Veterinarian:** [Contact information]\n- **After-hours:** [Emergency contact]\n\n---\n\n## 6. EXPERIMENTAL PROCEDURES\n\n### 6.1 Animals\n- **Species:** Laboratory mice (*Mus musculus*)\n- **Strain:** C57BL/6J\n- **Age:** 8-12 weeks\n- **Sex:** Both male and female (equal distribution)\n- **Source:** [Approved vendor]\n- **Acclimation:** Minimum 7 days before study initiation\n\n### 6.2 Housing and Husbandry\n- **Housing:** Individually ventilated cages, maximum 5 mice per cage\n- **Environment:** 12:12 light/dark cycle, 20-24\u00b0C, 40-60% humidity\n- **Diet:** Standard laboratory chow ad libitum\n- **Water:** Acidified water ad libitum\n- **Enrichment:** Nesting material, hiding structures\n\n### 6.3 Infection Model\n**Bacterial Strain:** [Specific gram-negative bacteria to be specified]\n**Inoculation Route:** Intraperitoneal injection\n**Dose:** 1\u00d710^6 CFU in 0.1 mL sterile saline\n**Timing:** Day 0 of study\n\n### 6.4 Amoxicillin Administration\n\n#### Preparation:\n1. Dissolve amoxicillin trihydrate in sterile saline (5-10 mg/mL)\n2. Filter sterilize through 0.22 \u03bcm filter\n3. Prepare fresh solution daily\n4. Verify pH (6.0-8.0)\n\n#### Administration Protocol:\n- **Dose:** 50 mg/kg body weight\n- **Route:** Intraperitoneal injection\n- **Frequency:** Every 12 hours (BID)\n- **Duration:** 7 days\n- **Volume:** Maximum 10 mL/kg\n- **Initiation:** 2 hours post-infection\n\n#### Procedure Steps:\n1. Weigh mouse and calculate dose\n2. Restrain mouse appropriately\n3. Identify injection site (lower right abdominal quadrant)\n4. Insert 25-gauge needle at 30-45\u00b0 angle\n5. Aspirate to confirm proper placement\n6. Inject solution slowly\n7. Monitor injection site and animal response\n\n### 6.5 Monitoring and Data Collection\n\n#### Clinical Observations (Daily):\n- Body weight (\u00b10.1g accuracy)\n- Clinical scoring (validated scale)\n- Food and water consumption\n- Behavioral assessment\n- Injection site evaluation\n\n#### Sample Collection:\n- **Blood samples:** 50-100 \u03bcL via submandibular bleeding\n- **Tissue samples:** At study termination for bacterial quantification\n- **Timing:** Days 1, 3, 5, 7, and 14 post-infection\n\n#### Endpoints:\n- **Primary:** Bacterial load (CFU/mL in blood and tissues)\n- **Secondary:** Survival rate, clinical score"
  },
  "errors": [],
  "reviewed_at": "2026-02-03T19:40:40.496657"
}